TNF binders

US9745372B2 · kind B2 · utility

Assignee

• Ablynx N.V. · BE

Inventors

• Marie-Ange Buyse · Merelbeke, BE
• Joachim BOUCNEAU · Zevergem, BE
• Peter Casteels · Bambrugge, BE
• Gino Van Heeke · Gainesville, US

Key dates

• Filing date: Mar 13, 2017
• Grant date: Aug 29, 2017
• Expiry date: Mar 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.